Breast disease最新文献

筛选
英文 中文
Impact of the COVID-19 pandemic on breast cancer pathological stage at diagnosis in Tunisian patients. COVID-19 大流行对突尼斯患者诊断时乳腺癌病理阶段的影响。
Breast disease Pub Date : 2024-01-01 DOI: 10.3233/BD-230051
Meriam Triki, Mouna Zghal, Houda Ben Ayed, Saadia Makni, Maroua Bouhamed, Semi Fendri, Slim Charfi, Tahya Boudawara, Manel Mellouli
{"title":"Impact of the COVID-19 pandemic on breast cancer pathological stage at diagnosis in Tunisian patients.","authors":"Meriam Triki, Mouna Zghal, Houda Ben Ayed, Saadia Makni, Maroua Bouhamed, Semi Fendri, Slim Charfi, Tahya Boudawara, Manel Mellouli","doi":"10.3233/BD-230051","DOIUrl":"10.3233/BD-230051","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) patients' diagnosis and management was affected by a global reorganization after the Coronavirus disease 2019 (COVID-19). Our study aimed to assess the impact of the pandemic on the pathological stage of newly diagnosed patients with BC compared to pre-pandemic and to identify predictive factors of tumor advanced stage.</p><p><strong>Methods: </strong>Pathological records of all consecutive newly operated BC patients between March 2020 and December 2021 were reviewed retrospectively. Clinical and pathological prognostic factors of BC were collected and compared between pre-pandemic and pandemic periods. Then, predictive factors of tumor advanced stage were identified.</p><p><strong>Results: </strong>Of the 225 cases included in the analysis, 98.7% were females and 1.3% were males. The median time from first histological diagnosis to first surgical treatment was enlarged by 42 days with a significant difference between the two periods (p = 0.002). Newly diagnosed BC patients during the COVID-19 pandemic were operated at a more advanced stage (54.1% vs 36.2%, p = 0.007), had a greater lymphovascular invasion (p = 0.002), lymph node metastasis (p = 0.015) and are more commonly of IBC NST histological type (p = 0.005). Moreover, multivariate analyses showed that the pandemic period (AOR = 2.28; p = 0.016) and the lympho-vascular invasion (p < 0.001) were independently associated with advanced stage of tumors.</p><p><strong>Conclusion: </strong>Our findings proved an increase in alarming rates of advanced stage BC associated with the COVID-19 crisis. These findings support recommendations for a quick restoration of BC screening at full capacity, with adequate prioritization strategies to mitigate harm.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"9-17"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10894576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to: Clinical significance of Notch receptors in triple negative breast cancer. 勘误:三阴性乳腺癌中 Notch 受体的临床意义。
Breast disease Pub Date : 2024-01-01 DOI: 10.3233/BD-229041
Heer Shah, Mittal Mistry, Nupur Patel, Hemangini Vora
{"title":"Erratum to: Clinical significance of Notch receptors in triple negative breast cancer.","authors":"Heer Shah, Mittal Mistry, Nupur Patel, Hemangini Vora","doi":"10.3233/BD-229041","DOIUrl":"https://doi.org/10.3233/BD-229041","url":null,"abstract":"","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"159"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metaplastic breast cancer masquerading as a recurrent haematoma: A case report. 伪装成复发性血肿的移行细胞乳腺癌:病例报告。
Breast disease Pub Date : 2024-01-01 DOI: 10.3233/BD-240006
Nicholas Chen Yi Png, Winfred Xi Tai Goh, Clement Wenhao Chan
{"title":"Metaplastic breast cancer masquerading as a recurrent haematoma: A case report.","authors":"Nicholas Chen Yi Png, Winfred Xi Tai Goh, Clement Wenhao Chan","doi":"10.3233/BD-240006","DOIUrl":"10.3233/BD-240006","url":null,"abstract":"<p><p>An 85-year-old Chinese lady presented with a 5-day history of a painless left breast lump. There was no fever, nipple discharge, or history of trauma. She had a past medical history of atrial fibrillation that was managed with an oral anticoagulant. Mammography demonstrated a dense mass in the upper outer quadrant of the left breast. Ultrasound showed an irregular, heterogeneous 4.7 cm lesion containing debris and cystic spaces with raised peripheral vascularity at the 2 o'clock position, 3 cm from nipple. No internal vascularity was detected. This was managed as a haematoma and rivaroxaban was withheld. Follow-up imaging 3-weeks later showed persistence of the lesion. Bedside needle aspiration yielded haemoserous fluid with immediate reduction in size of the lesion. However, 2 weeks after aspiration, there was recurrence of the 'haematoma'. Multidisciplinary review of the clinical history, examination and imaging was sought, and biopsy of the irregularly thickened areas with vascularity along the periphery of the lesion was recommended. Vacuum-assisted biopsy was performed, and histology returned as metaplastic carcinoma. A recurring 'haematoma' should always prompt a search for a secondary cause, with features such as irregular thickened walls and papillary/nodular components requiring further evaluation with biopsy for histopathological correlation.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"187-191"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Massage on the prevention of breast cancer through stress reduction and enhancing immune system. 通过减轻压力和增强免疫系统来预防乳腺癌的按摩。
Breast disease Pub Date : 2024-01-01 DOI: 10.3233/BD-249009
Zilhana Siregar, Andi Nilawati Usman, Mardiana Ahmad, Andi Ariyandy, Ilhamuddin Ilhamuddin, A B Takko
{"title":"Massage on the prevention of breast cancer through stress reduction and enhancing immune system.","authors":"Zilhana Siregar, Andi Nilawati Usman, Mardiana Ahmad, Andi Ariyandy, Ilhamuddin Ilhamuddin, A B Takko","doi":"10.3233/BD-249009","DOIUrl":"10.3233/BD-249009","url":null,"abstract":"<p><strong>Introduction: </strong>Housewives are a population at high risk of breast cancer due to repeated or chronic exposure to stress. Prevention in a simple yet evidence-based manner is needed.</p><p><strong>Methods: </strong>This study is a narrative review of the potential of massage as breast cancer prevention through stress and immune system mechanisms.</p><p><strong>Results: </strong>Massage is able to prevent chronic stress through improved sleep and fatigue and lower stress levels. Prevention of chronic stress will maximize the function of cells that eliminate cancer cells, such as B cells, T cells, and natural killer (NK) cells, and improve the balance of Foxp3 Tregulator cells. Partnered delivery massage will bring effective benefits for stress reduction.</p><p><strong>Conclusions: </strong>Massage can provide indirect prevention of breast cancer, and partnered delivery massage can be a good choice to reduce stress.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"119-126"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of axillary ultrasound to guide breast cancer management in the genomic assay era. 在基因组检测时代利用腋窝超声指导乳腺癌治疗。
Breast disease Pub Date : 2024-01-01 DOI: 10.3233/BD-230032
Geok Hoon Lim, John Carson Allen, Yien Sien Lee, Sze Yiun Teo, Li Ching Lau, Thida Win, Lester Chee Hao Leong
{"title":"Use of axillary ultrasound to guide breast cancer management in the genomic assay era.","authors":"Geok Hoon Lim, John Carson Allen, Yien Sien Lee, Sze Yiun Teo, Li Ching Lau, Thida Win, Lester Chee Hao Leong","doi":"10.3233/BD-230032","DOIUrl":"10.3233/BD-230032","url":null,"abstract":"<p><strong>Introduction: </strong>Chemotherapy is conventionally offered to non-stage IV breast cancer patients with metastatic nodes. However, the RxPONDER trial showed that chemotherapy can be omitted in selected patients with 1-3 metastatic nodes if the 21-gene assay recurrence score is ≤25. We aimed to investigate if axillary ultrasound can identify this group of patients with limited nodal burden so that they can undergo upfront surgery followed by gene assay testing, to potentially avoid chemotherapy.</p><p><strong>Methods: </strong>T1-3, node positive, hormone receptor-positive and HER2-negative breast cancer patients ≥50 years old with axillary lymph node dissection (ALND) were reviewed from 2 centres. Patients with neoadjuvant chemotherapy and bilateral cancers were excluded. Number of ultrasound-detected abnormal axillary nodes, demographic and histological parameters were correlated with the number of metastatic nodes found on ALND.</p><p><strong>Results: </strong>138 patients were included, 59 (42.8%) and 79 (57.2%) patients had 1-3 and >3 metastatic nodes on ALND respectively. On logistic regression and ROC analysis, the number of ultrasound-detected abnormal nodes was significant (p < 0.001) for predicting limited nodal burden (ROC AUC = 0.7135). Probabilities of <4 metastatic nodes with ultrasound cut-offs of 5, 6 and 8 abnormal nodes were 0.057, 0.026 and 0.005 respectively, with 100% specificity.</p><p><strong>Conclusion: </strong>A cut-off of ≤5 ultrasound-detected abnormal nodes can distinguish between patients with limited versus high nodal burden, with high specificity. Hence, incorporating the number of abnormal ultrasound-detected nodes into clinical practice may prove useful in guiding between upfront surgery and gene assay testing or neoadjuvant chemotherapy in this group of patients.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"19-23"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10977404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140136509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pleiotrophin serum level and metastasis occurrence in breast cancer patients. 乳腺癌患者的Pleiotrophin血清水平与转移发生率
Breast disease Pub Date : 2024-01-01 DOI: 10.3233/BD-249003
Muhamad Ikhlas, Djonny Ferianto, Salman Ardi Syamsu, Idham Jaya Ganda, Nilam Smaradania, Elridho Sampepajung, Citra Azma Anggita, Muhammad Faruk
{"title":"Pleiotrophin serum level and metastasis occurrence in breast cancer patients.","authors":"Muhamad Ikhlas, Djonny Ferianto, Salman Ardi Syamsu, Idham Jaya Ganda, Nilam Smaradania, Elridho Sampepajung, Citra Azma Anggita, Muhammad Faruk","doi":"10.3233/BD-249003","DOIUrl":"10.3233/BD-249003","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) cases in Makassar, Indonesia, are on the rise, with 2723 cases recorded in 2018. Tumor cells in the blood indicate metastasis, emphasizing the need for early diagnosis and monitoring. Pleiotrophin (PTN) is associated with various human malignancies, and recent studies suggest a correlation between PTN expression and advanced BC stages; therefore, PTN could serve as an independent predictor of metastasis. This study aimed to determine the correlation between serum PTN level, histopathological grading, and metastasis occurrence in BC patients in Makassar, Indonesia.</p><p><strong>Methods: </strong>This study used an observational cross-sectional design. Pleiotrophin serum levels were examined using enzyme-linked immunosorbent assays. This study used a t-test and ROC curve analysis for the statistical tests.</p><p><strong>Results: </strong>Of the 64 samples used in this study, metastasis was present in 26 cases and absent in 38 samples. The mean PTN serum levels in metastatic and non-metastatic breast cancer patients were 4.311 and 1.253, respectively. The PTN receiver operating characteristic curve showed an area under the curve of 2.47 ng/dL, which was statistically significant (p < 0.001). A significant relationship was found between PTN level and metastasis (p < 0.001). The correlation coefficient was 0.791, indicating a positive correlation.</p><p><strong>Conclusion: </strong>This study revealed that the serum PTN level among breast cancer patients had a cut-off value of 2.47 ng/dL. The research established a clear correlation between PTN level and metastasis occurrence in breast cancer patients, indicating a higher likelihood of distant metastasis with elevated PTN concentration.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"93-98"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-IL-8 monoclonal antibodies inhibits the autophagic activity and cancer stem cells maintenance within breast cancer tumor microenvironment. 抗IL-8单克隆抗体可抑制乳腺癌肿瘤微环境中的自噬活性和癌症干细胞的维持。
Breast disease Pub Date : 2024-01-01 DOI: 10.3233/BD-230052
Seham Abou Shousha, Eman M Osman, Suzan Baheeg, Yasmine Shahine
{"title":"Anti-IL-8 monoclonal antibodies inhibits the autophagic activity and cancer stem cells maintenance within breast cancer tumor microenvironment.","authors":"Seham Abou Shousha, Eman M Osman, Suzan Baheeg, Yasmine Shahine","doi":"10.3233/BD-230052","DOIUrl":"10.3233/BD-230052","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer tumor microenvironment (TME) is a promising target for immunotherapy. Autophagy, and cancer stem cells (CSCs) maintenance are essential processes involved in tumorigenesis, tumor survival, invasion, and treatment resistance. Overexpression of angiogenic chemokine interleukin-8 (IL-8) in breast cancer TME is associated with oncogenic signaling pathways, increased tumor growth, metastasis, and poor prognosis.</p><p><strong>Objective: </strong>Thus, we aimed to investigate the possible anti-tumor effect of neutralizing antibodies against IL-8 by evaluating its efficacy on autophagic activity and breast CSC maintenance.</p><p><strong>Methods: </strong>IL-8 monoclonal antibody supplemented tumor tissue culture systems from 15 females undergoing mastectomy were used to evaluate the expression of LC3B as a specific biomarker of autophagy and CD44, CD24 as cell surface markers of breast CSCs using immunofluorescence technique.</p><p><strong>Results: </strong>Our results revealed that anti-IL-8 mAb significantly decreased the level of LC3B in the cultured tumor tissues compared to its non-significant decrease in the normal breast tissues.Anti-IL-8 mAb also significantly decreased the CD44 expression in either breast tumors or normal cultured tissues. While it caused a non-significant decrease in CD24 expression in cultured breast tumor tissue and a significant decrease in its expression in the corresponding normal ones.</p><p><strong>Conclusions: </strong>Anti-IL-8 monoclonal antibody exhibits promising immunotherapeutic properties through targeting both autophagy and CSCs maintenance within breast cancer TME.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"37-49"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10977415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140326354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer associated fibroblasts modulate the cytotoxicity of anti-cancer drugs in breast cancer: An in vitro study. 癌症相关成纤维细胞调节乳腺癌抗癌药物的细胞毒性:体外研究
Breast disease Pub Date : 2024-01-01 DOI: 10.3233/BD-230011
Dharambir Kashyap, Shalmoli Bhattacharya, Santosh Irinike, Siddhant Khare, Ashim Das, Gurpreet Singh, Amanjit Bal
{"title":"Cancer associated fibroblasts modulate the cytotoxicity of anti-cancer drugs in breast cancer: An in vitro study.","authors":"Dharambir Kashyap, Shalmoli Bhattacharya, Santosh Irinike, Siddhant Khare, Ashim Das, Gurpreet Singh, Amanjit Bal","doi":"10.3233/BD-230011","DOIUrl":"10.3233/BD-230011","url":null,"abstract":"<p><strong>Background: </strong>Tumour microenvironment (TME) contributes to resistance to anti-cancer drugs through multiple mechanisms including secretion of pro-survival factors by cancer associated fibroblasts (CAFs). In this study, we determined the chemotherapy resistance producing potential of CAFs in molecular subtypes of breast cancer.</p><p><strong>Methods: </strong>The CAFs were isolated from fresh lumpectomy/mastectomy specimens of different molecular subtypes of breast cancer. The CAFs were cultured and secretome was collected from each breast cancer subtype. Breast cancer cell lines MCF-7, SK-BR3, MDA-MB-231, and MDA-MB-468 were treated with different doses of tamoxifen, trastuzumab, cisplatin, and doxorubicin alone respectively and in combination with secretome of CAFs from respective subtypes. MTT assay was done to check cell death after drug treatment. Liquid chromatography-mass spectrometry (LCMS) analysis of CAF secretome was also done.</p><p><strong>Results: </strong>MTT assay showed that anti-cancer drugs alone had growth inhibitory effect on the cancer cells however, presence of CAF secretome reduced the anti-cancer effect of the drugs. Resistant to drugs in the presence of secretome, was determined by increased cell viability i.e., MCF-7, 51.02% to 63.02%; SK-BR-3, 34.22% to 44.88%; MDA-MB-231, 52.59% to 78.63%; and MDA-MB-468, 48.92% to 55.08%. LCMS analysis of the secretome showed the differential abundance of CAFs secreted proteins across breast cancer subtypes.</p><p><strong>Conclusions: </strong>The treatment of breast cancer cell lines with anti-cancer drugs in combination with secretome isolated from molecular subtype specific CAFs, reduced the cytotoxic effect of the drugs. In addition, LCMS data also highlighted different composition of secreted proteins from different breast cancer associated fibroblasts. Thus, TME has heterogenous population of CAFs across the breast cancer subtypes and in vitro experiments highlight their contribution to chemotherapy resistance which needs further validation.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"25-36"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10977379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140189412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis. 通过HRM-COLD-PCR分析发现乳腺癌患者中的一种新型PIK3CA热点突变。
Breast disease Pub Date : 2024-01-01 DOI: 10.3233/BD-240005
Saoussen Debouki-Joudi, Wala Ben Kridis, Fatma Trifa, Wajdi Ayadi, Abdelmajid Khabir, Tahia Sellami-Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad-Gargouri
{"title":"A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis.","authors":"Saoussen Debouki-Joudi, Wala Ben Kridis, Fatma Trifa, Wajdi Ayadi, Abdelmajid Khabir, Tahia Sellami-Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad-Gargouri","doi":"10.3233/BD-240005","DOIUrl":"10.3233/BD-240005","url":null,"abstract":"<p><strong>Background: </strong>The PI3K protein is involved in the PI3K/AKT/mTOR pathway. Deregulation of this pathway through PIK3CA mutation is common in various tumors. The aim of this work is to identify hotspot mutation at exons 9 and 20 in Tunisian patients with sporadic or hereditary breast cancer.</p><p><strong>Methods: </strong>Hotspot mutations in exon 9 and exon 20 of the PIK3CA gene were identified by QPCR-High Resolution Melting followed by COLD-PCR and sequencing in 63 (42 sporadic cases and 21 hereditary cases) tumor tissues collected from Tunisian patient with breast cancer. MCF7, and BT20 breast cancer cell lines harboring the PIK3CA hotspot mutations E545K and H1047R in exon 9 and exon 20 respectively, were used as controls in HRM experiments.</p><p><strong>Results: </strong>PIK3CA hotspot mutations were detected in 66.7% (28 out of 42) of sporadic BC cases, and in 14.3% (3 out of 21) of hereditary BC. The E545K and the H1048Y were the most prevalent mutations identified in patients with sporadic and hereditary BC, whereas the H1047R hotspot mutation was not found in our patients. Statistical analysis showed that PIK3CA mutation associated with an aggressive behavior in patients with sporadic BC, while it's correlated with age, tumor stage and tumor size in the group patients with hereditary breast cancer.</p><p><strong>Conclusions: </strong>Our results showed a novel PIK3CA hotspot mutation in Tunisian breast cancer patients detected by HRM-COLD-PCR. Moreover, the absence of PIK3CA hotspot mutation associated with good prognosis.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"213-221"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PD-1/PD-L1 pathway: Current research in breast cancer. PD-1/PD-L1 通路:乳腺癌研究现状
Breast disease Pub Date : 2024-01-01 DOI: 10.3233/BD-249006
Salman Ardi Syamsu, Muhammad Faruk, Nilam Smaradania, Elridho Sampepajung, Agung Sindu Pranoto, Febie Irsandy, Iin Fadhilah Utami Tammasse
{"title":"PD-1/PD-L1 pathway: Current research in breast cancer.","authors":"Salman Ardi Syamsu, Muhammad Faruk, Nilam Smaradania, Elridho Sampepajung, Agung Sindu Pranoto, Febie Irsandy, Iin Fadhilah Utami Tammasse","doi":"10.3233/BD-249006","DOIUrl":"10.3233/BD-249006","url":null,"abstract":"<p><strong>Introduction: </strong>Immunotherapy has shown encouraging outcomes in breast cancer (BC) treatment in recent years. The programmed cell death ligand 1 (PD-L1) transmembrane protein is suggested to function as a co-inhibitory factor in the immune response, where it collaborates with programmed cell death protein 1 (PD-1) to stimulate apoptosis, suppress cytokine release from PD-1 positive cells, and limit the growth of PD-1 positive cells. Furthermore, in many malignancies, PD-L1 reduces the immune system's response to neoplastic cells. These observations suggest that the PD-1/PD-L1 axis plays a vital role in cancer therapy and the regulation of cancer immune escape mechanisms. This review aimed to provide an overview of the functions of PD-1 and PD-L1 in BC cancer therapy.</p><p><strong>Methods: </strong>This research design is a literature review. The style is a traditional review on topics or variables relating to the PD-1/PD-L1 pathway. A literature search was carried out using three online databases.</p><p><strong>Results: </strong>The search using the keywords yielded a total of 248 studies. Each result was filtered again according to the inclusion and exclusion criteria, resulting in a final total of 4 studies to be included in the literature review.</p><p><strong>Conclusions: </strong>The combination of PD-1/PD-L1 is essential for many malignancies. According to the evidence presented, this combination presents both an opportunity and a challenge in cancer treatment. Since many solid cancers, especially BC, express high levels of PD-1/PD-L1, cancer treatment mainly involves targeted therapies.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"79-92"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信